Shinsei Capital Partners
Venture capitalTokyo · Pre-Seed–Late Stage
Also known as 新生キャピタルパートナーズ株式会社
Investment thesis
The firm sees Japan's life sciences sector as globally competitive thanks to sustained research by universities, institutions, and pharmaceutical companies. Its mission is to financially support these research outcomes to bring innovative medicines to patients and drive practical commercialization. Managing the New Life Science No.1 fund, it invests in drug-discovery ventures across company creation, seed, early, middle, and later stages, drawing on decades of combined expertise in finance and drug development to enable technology-driven innovation in healthcare.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 6 of 7 portfolio companiesBiotech ×6Deep Tech ×4Healthtech ×4Medical Devices ×3AI & Machine Learning ×1Digital Health ×1
HQs:Japan×6
Investments · 7 tracked
founders shown can be your intro pathAlphaNavi Pharma is a pharmaceutical company developing new drugs (Nav channel inhibitors) for patients suffering from chronic pain and neurological disorders.
BiotechDigital HealthHealthtech京都市, JP
小山田義博Yoshihiro Oyamada(Representative Director)
FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases.
BiotechDeep TechMedical DevicesFujisawa, JP
福田 将虎(Founder & Scientific Advisor)高橋 信明(代表取締役社長・CEO (President & CEO))
MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics.
BiotechDeep TechHealthtechTokyo, JP
Hiroaki Suga(Co-founder; Professor, University of Tokyo)Masuhiro Kato(Representative Director & President)Junichi Takagi(Co-founder; Director & Professor, Osaka University)Igarashi(Chief Operating Officer)
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
AI & Machine LearningBiotechDeep TechMedical DevicesKawasaki, JP
Shingo Nakamura(CEO)
TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services.
BiotechHealthtechMedical DevicesHiroshima, JP
松本 昌也(代表取締役社長)
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Portfolio news
latest coverage across their companiesVeritas In Silico · finance.yahoo.com · Apr 21, 2026
Frequently asked questions
- What stage does Shinsei Capital Partners invest at?
- Shinsei Capital Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Shinsei Capital Partners focus on?
- Shinsei Capital Partners focuses on Biotech, Digital Health, Sector Agnostic.
- Where is Shinsei Capital Partners located?
- Shinsei Capital Partners is headquartered in Tokyo, JP.
Images
Similar investors
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
General Catalyst is a venture capital and investment firm that backs founders across industries, with a strong focus on AI-driven transformation, fintech, healthcare, and other sectors.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.